Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.

Schairer C, Hablas A, Eldein IAS, Gaafar R, Rais H, Mezlini A, Ayed FB, Ayoub WB, Benider A, Tahri A, Khouchani M, Aboulazm D, Karkouri M, Eissa S, Pfeiffer RM, Gadalla SM, Swain SM, Merajver SD, Brown LM, Soliman AS.

Breast Cancer Res Treat. 2019 Jul;176(2):407-417. doi: 10.1007/s10549-019-05237-5. Epub 2019 Apr 22.

PMID:
31006821
2.

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.

Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R.

Future Oncol. 2019 Jun;15(17):1951-1961. doi: 10.2217/fon-2019-0059. Epub 2019 Apr 12.

PMID:
30977385
3.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.

Kim RS, Song N, Gavin PG, Salgado R, Bandos H, Kos Z, Floris G, Eynden GGVD, Badve S, Demaria S, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Lawrence Wickerham D, Costantino JP, Paik S, Wolmark N, Geyer CE, Lucas PC, Pogue-Geile KL.

J Natl Cancer Inst. 2019 Mar 19. pii: djz032. doi: 10.1093/jnci/djz032. [Epub ahead of print]

PMID:
30888406
4.

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.

Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM.

Breast Cancer Res Treat. 2019 Jun;175(3):595-603. doi: 10.1007/s10549-019-05191-2. Epub 2019 Mar 9.

5.

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy538. [Epub ahead of print] No abstract available.

PMID:
30624595
6.

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.

Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M.

Clin Cancer Res. 2019 Apr 15;25(8):2433-2441. doi: 10.1158/1078-0432.CCR-18-2366. Epub 2018 Dec 28.

PMID:
30593513
7.

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N.

Lancet Oncol. 2019 Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. Epub 2018 Nov 30. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30509771
8.

Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?

Dang CT, Blaes A, Lynce F, Swain SM, Dent S.

JACC Cardiovasc Imaging. 2018 Aug;11(8):1094-1097. doi: 10.1016/j.jcmg.2018.02.027. No abstract available.

PMID:
30092968
9.

CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.

Lynce F, Shajahan-Haq AN, Swain SM.

Pharmacol Ther. 2018 Nov;191:65-73. doi: 10.1016/j.pharmthera.2018.06.008. Epub 2018 Jun 19. Review.

10.

Piezo1 is a mechanically activated ion channel and mediates pressure induced pancreatitis.

Romac JM, Shahid RA, Swain SM, Vigna SR, Liddle RA.

Nat Commun. 2018 Apr 30;9(1):1715. doi: 10.1038/s41467-018-04194-9.

11.

Luminal A Breast Cancer and Molecular Assays: A Review.

Gao JJ, Swain SM.

Oncologist. 2018 May;23(5):556-565. doi: 10.1634/theoncologist.2017-0535. Epub 2018 Feb 22. Review.

12.

TEOSINTE BRANCHED1 Regulates Inflorescence Architecture and Development in Bread Wheat (Triticum aestivum).

Dixon LE, Greenwood JR, Bencivenga S, Zhang P, Cockram J, Mellers G, Ramm K, Cavanagh C, Swain SM, Boden SA.

Plant Cell. 2018 Mar;30(3):563-581. doi: 10.1105/tpc.17.00961. Epub 2018 Feb 14.

13.

Zebularine treatment is associated with deletion of FT-B1 leading to an increase in spikelet number in bread wheat.

Finnegan EJ, Ford B, Wallace X, Pettolino F, Griffin PT, Schmitz RJ, Zhang P, Barrero JM, Hayden MJ, Boden SA, Cavanagh CA, Swain SM, Trevaskis B.

Plant Cell Environ. 2018 Jun;41(6):1346-1360. doi: 10.1111/pce.13164. Epub 2018 Apr 6. Erratum in: Plant Cell Environ. 2019 Feb;42(2):751.

PMID:
29430678
14.

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J.

Ann Oncol. 2018 Jul 1;29(7):1607. doi: 10.1093/annonc/mdx802. No abstract available.

PMID:
29300831
15.

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.

Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group.

Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773.

16.

Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial.

Miles D, Im YH, Fung A, Yoo B, Knott A, Heeson S, Beattie MS, Swain SM.

Ann Oncol. 2017 Nov 1;28(11):2761-2767. doi: 10.1093/annonc/mdx406.

PMID:
29112701
17.

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.

Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N.

J Clin Oncol. 2017 Dec 10;35(35):3942-3948. doi: 10.1200/JCO.2017.74.1165. Epub 2017 Oct 26.

18.

CO-independent modification of K+ channels by tricarbonyldichlororuthenium(II) dimer (CORM-2).

Gessner G, Sahoo N, Swain SM, Hirth G, Schönherr R, Mede R, Westerhausen M, Brewitz HH, Heimer P, Imhof D, Hoshi T, Heinemann SH.

Eur J Pharmacol. 2017 Nov 15;815:33-41. doi: 10.1016/j.ejphar.2017.10.006. Epub 2017 Oct 5.

19.

Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.

Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx162.

20.

Video intervention increases participation of black breast cancer patients in therapeutic trials.

Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann PR, Mohebtash M, Lee Y, Ottaviano Y, Mohapatra A, Lynce F, Brown R, Mete M, Swain SM.

NPJ Breast Cancer. 2017 Sep 18;3:36. doi: 10.1038/s41523-017-0039-1. eCollection 2017.

21.

Take care of your neighborhood.

Huerta EE, Weeks-Coulthurst P, Williams C, Swain SM.

Breast Cancer Res Treat. 2018 Jan;167(1):225-234. doi: 10.1007/s10549-017-4492-1. Epub 2017 Sep 12.

PMID:
28900788
22.

Focus on You: Cancer clinical trials perspectives.

Robinson BN, Newman AF, Wallington SF, Swain SM.

Contemp Clin Trials Commun. 2016 Dec 15;4:170-178. doi: 10.1016/j.conctc.2016.09.004. Epub 2016 Sep 16.

23.

New alleles of the wheat domestication gene Q reveal multiple roles in growth and reproductive development.

Greenwood JR, Finnegan EJ, Watanabe N, Trevaskis B, Swain SM.

Development. 2017 Jun 1;144(11):1959-1965. doi: 10.1242/dev.146407. Epub 2017 Apr 28.

24.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N.

J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.

25.

SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.

Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, Isaacs C, Swain SM.

Oncologist. 2017 May;22(5):518-525. doi: 10.1634/theoncologist.2016-0412. Epub 2017 Mar 17.

26.

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J.

Ann Oncol. 2017 Apr 1;28(4):761-768. doi: 10.1093/annonc/mdw695.

27.

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S.

Lancet Oncol. 2017 Jan;18(1):52-62. doi: 10.1016/S1470-2045(16)30631-3. Epub 2016 Dec 7. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667.

28.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.

Ann Surg Oncol. 2017 Jul;24(7):1853-1860. doi: 10.1245/s10434-016-5662-9. Epub 2016 Nov 18.

29.

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.

Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Jeong JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL.

JAMA Oncol. 2017 Mar 1;3(3):335-341. doi: 10.1001/jamaoncol.2016.4884.

30.

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.

Smith JW 2nd, Buyse ME, Rastogi P, Geyer CE Jr, Jacobs SA, Patocskai EJ, Robidoux A, Conlin AK, Ansari B, Keogh GP, Stella PJ, Gross HM, Lord RS, Polikoff JA, Mauquoi C, Mamounas EP, Swain SM, Wolmark N.

Clin Breast Cancer. 2017 Feb;17(1):48-54.e3. doi: 10.1016/j.clbc.2016.07.008. Epub 2016 Jul 28.

PMID:
27693116
31.

HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.

Gao JJ, Tan M, Pohlmann PR, Swain SM.

Clin Breast Cancer. 2017 Feb;17(1):76-78. doi: 10.1016/j.clbc.2016.08.005. Epub 2016 Aug 27.

32.

Genomic profiling of breast cancer in African-American women using MammaPrint.

Nunes RA, Wray L, Mete M, Herbolsheimer P, Smith KL, Bijelic L, Boisvert ME, Swain SM.

Breast Cancer Res Treat. 2016 Oct;159(3):481-8. doi: 10.1007/s10549-016-3949-y. Epub 2016 Aug 27.

PMID:
27568021
33.

Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies?

Barac A, Swain SM.

JAMA Oncol. 2016 Aug 1;2(8):1037-9. doi: 10.1001/jamaoncol.2016.0283. No abstract available.

PMID:
27356170
34.

Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?

Ewer MS, Swain SM.

Oncologist. 2016 Apr;21(4):399-401. doi: 10.1634/theoncologist.2016-0069. Epub 2016 Mar 16. No abstract available.

35.

Pertuzumab for the treatment of breast cancer: a safety review.

Gao J, Swain SM.

Expert Opin Drug Saf. 2016 Jun;15(6):853-63. doi: 10.1517/14740338.2016.1167185. Epub 2016 Apr 12. Review.

PMID:
26982349
36.

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S.

Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z. Epub 2016 Jan 12.

37.

Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.

Barac A, Lynce F, Smith KL, Mete M, Shara NM, Asch FM, Nardacci MP, Wray L, Herbolsheimer P, Nunes RA, Swain SM, Warren R, Peshkin BN, Isaacs C.

Breast Cancer Res Treat. 2016 Jan;155(2):285-93. doi: 10.1007/s10549-016-3678-2. Epub 2016 Jan 9.

PMID:
26749359
38.

Does CDKN2A loss predict palbociclib benefit?

Gao J, Adams RP, Swain SM.

Curr Oncol. 2015 Dec;22(6):e498-501. doi: 10.3747/co.22.2700.

39.

Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age.

Swain SM, Nunes R, Yoshizawa C, Rothney M, Sing AP.

Adv Ther. 2015 Dec;32(12):1222-36. doi: 10.1007/s12325-015-0268-3. Epub 2015 Nov 26.

40.

Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38.

Cecchini RS, Swain SM, Costantino JP, Rastogi P, Jeong JH, Anderson SJ, Tang G, Geyer CE Jr, Lembersky BC, Romond EH, Paterson AH, Wolmark N.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):51-9. doi: 10.1158/1055-9965.EPI-15-0334-T. Epub 2015 Nov 6.

41.

Ca(2+)/calmodulin regulates Kvβ1.1-mediated inactivation of voltage-gated K(+) channels.

Swain SM, Sahoo N, Dennhardt S, Schönherr R, Heinemann SH.

Sci Rep. 2015 Oct 21;5:15509. doi: 10.1038/srep15509.

42.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.

Lancet Oncol. 2015 Sep;16(9):1037-1048. doi: 10.1016/S1470-2045(15)00041-8. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

43.

Treatment of HER2-positive metastatic breast cancer.

Swain SM, Clark E, Baselga J.

N Engl J Med. 2015 May 14;372(20):1964-5. doi: 10.1056/NEJMc1503446. No abstract available.

44.

Reply to a. Avan et Al.

Baselga J, Clark E, Kiermaier A, Swain SM.

J Clin Oncol. 2015 May 20;33(15):1712. doi: 10.1200/JCO.2015.60.8398. Epub 2015 Apr 13. No abstract available. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):354.

PMID:
25870094
45.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group.

N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.

46.

Improving Documentation of Pain Management at MedStar Washington Cancer Institute.

Ranpura V, Agrawal S, Chokshi P, Yerasi C, Wood L, Beasley J, Harkness J, Heller S, Self L, Swain SM, Jang S.

J Oncol Pract. 2015 Mar;11(2):155-7. doi: 10.1200/JOP.2014.001636. Epub 2015 Feb 17.

PMID:
25690597
47.

A genetic strategy generating wheat with very high amylose content.

Regina A, Berbezy P, Kosar-Hashemi B, Li S, Cmiel M, Larroque O, Bird AR, Swain SM, Cavanagh C, Jobling SA, Li Z, Morell M.

Plant Biotechnol J. 2015 Dec;13(9):1276-86. doi: 10.1111/pbi.12345. Epub 2015 Feb 3.

48.

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

Pogue-Geile KL, Song N, Jeong JH, Gavin PG, Kim SR, Blackmon NL, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Clin Oncol. 2015 Apr 20;33(12):1340-7. doi: 10.1200/JCO.2014.56.2439. Epub 2015 Jan 5.

49.

Ppd-1 is a key regulator of inflorescence architecture and paired spikelet development in wheat.

Boden SA, Cavanagh C, Cullis BR, Ramm K, Greenwood J, Jean Finnegan E, Trevaskis B, Swain SM.

Nat Plants. 2015 Jan 26;1:14016. doi: 10.1038/nplants.2014.16.

PMID:
27246757
50.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

Tan AR, Johannes H, Rastogi P, Jacobs SA, Robidoux A, Flynn PJ, Thirlwell MP, Fehrenbacher L, Stella PJ, Goel R, Julian TB, Provencher L, Bury MJ, Bhatt K, Geyer CE Jr, Swain SM, Mamounas EP, Wolmark N.

Breast Cancer Res Treat. 2015 Jan;149(1):163-9. doi: 10.1007/s10549-014-3221-2. Epub 2014 Dec 27.

PMID:
25542269

Supplemental Content

Loading ...
Support Center